Robert Kralovics

Center for Molecular Medicine, Austrian Academy of Sciences, Austria
Professor

Scopus Profile: link
Web of Science profile: link
Profile Google Scholar: link
ID ORCID: http://orcid.org/0000-0002-6997-8539

Professional (scientific) interests: Hematopoietic malignancies (genetics and therapy); Cancer genetics

Selected Publications:

  1. Schischlik, F., Jäger, R., Rosebrock, F., Hug, E., Schuster, M., Holly, R., ... Kralovics, R. (2019). Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood, 134 (2), 199–210. doi: http://doi.org/10.1182/blood.2019000519
  1. Pecquet, C., Chachoua, I., Roy, A., Balligand, T., Vertenoeil, G., Leroy, E., ... Kralovics, R., Constantinescu, S. N. (2019). Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Blood, 133 (25), 2669–2681. doi: http://doi.org/10.1182/blood-2018-09-874578
  1. Sdelci, S., Rendeiro, A. F., Rathert, P., You, W., Lin, J.-M. G., Ringler, A., … Kralovics, R., Kubicek, S. (2019). MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nature Genetics, 51 (6), 990–998. doi: http://doi.org/10.1038/s41588-019-0413-z
  1. Uras, I. Z., Maurer, B., Nivarthi, H., Jodl, P., Kollmann, K., Prchal-Murphy, M., … Kralovics, R., Sexl, V. (2019). CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks. Blood, 133 (15), 1677–1690. doi: http://doi.org/10.1182/blood-2018-08-872648
  1. Balligand, T., Achouri, Y., Pecquet, C., Gaudray, G., Colau, D., Hug, E., … Kralovics, R., Constantinescu, S. N. (2019). Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. Leukemia. doi: http://doi.org/10.1038/s41375-019-0538-1
  1. Bigenzahn, J. W., Collu, G. M., Kartnig, F., Pieraks, M., Vladimer, G. I., Heinz, L. X., … Kralovics, R., Superti-Furga, G. (2018). LZTR1 is a regulator of RAS ubiquitination and signaling. Science, 362 (6419), 1171–1177. doi: http://doi.org/10.1126/science.aap8210
  1. Mughal, T. I., Lion, T., Abdel‐Wahab, O., Mesa, R., Scherber, R. M., Perrotti, D. et. al. (2018). Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematological Oncology, 36 (5), 740–748. doi: http://doi.org/10.1002/hon.2537